UPC_CFI_195/2025

METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)

InfringementMain Infringement ActionDusseldorf LDInfringementWritten Phase

Overview Decisions Documents Timeline

Parties

Claimants

Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc.

Reps: Niels Hölder (HOFFMANN EITLE PartmbB); Mike Gruber (HOFFMANN EITLE PartmbB); Michael Pfeifer (HOFFMANN EITLE PartmbB); Daniel Wise (CARPMAELS & RANSFORD); Agathe Michel-De Cazotte (CARPMAELS & RANSFORD)

Respondents

Amgen Inc.(Amgen Group)

Reps: Johannes Heselberger (BARDEHLE PAGENBERG Partnerschaft mbB); Nadine Westermeyer (BARDEHLE PAGENBERG Partnerschaft mbB)

Judges

Berenice Thom
Berenice Thom
Andras Kupecz
Xavier Dorland-Galliot

Patents

EP4252857
EP 4 252 857

CPC codes: A61K39/3955, C07K2317/76, A61P9/00, A61P43/00, A61P27/02, C07K2317/21, A61P7/00, C07K16/40, A61K2039/505, A61P11/00, A61P3/06, A61P9/10

Technology area: Pharmaceuticals · Antibody Therapy

Sector: Organic Chemistry

Outcome

Procedural onlyProcedural only (no substantive ruling yet)

Filed: Feb 28, 2025

First decided: —

Language: English

Open on UPC Registry